EQUAL-quant: an international external quality assessment scheme for real-time PCR.

BACKGROUND Quantitative gene expression analysis by real-time PCR is important in several diagnostic areas, such as the detection of minimum residual disease in leukemia and the prognostic assessment of cancer patients. To address quality assurance in this technically challenging area, the European Union (EU) has funded the EQUAL project to develop methodologic external quality assessment (EQA) relevant to diagnostic and research laboratories among the EU member states. We report here the results of the EQUAL-quant program, which assesses standards in the use of TaqMan probes, one of the most widely used assays in the implementation of real-time PCR. METHODS The EQUAL-quant reagent set was developed to assess the technical execution of a standard TaqMan assay, including RNA extraction, reverse transcription, and real-time PCR quantification of target DNA copy number. RESULTS The multidisciplinary EQA scheme included 137 participating laboratories from 29 countries. We demonstrated significant differences in performance among laboratories, with 20% of laboratories reporting at least one result lacking in precision and/or accuracy according to the statistical procedures described. No differences in performance were observed for the >10 different testing platforms used by the study participants. CONCLUSIONS This EQA scheme demonstrated both the requirement and demand for external assessment of technical standards in real-time PCR. The reagent design and the statistical tools developed within this project will provide a benchmark for defining acceptable working standards in this emerging technology.

[1]  One-step real-time duplex reverse transcription PCRs simultaneously quantify analyte and housekeeping gene mRNAs. , 2004, BioTechniques.

[2]  T. Lion.  Current recommendations for positive controls in RT-PCR assays , 2001, Leukemia.

[3]  H. Burkardt,et al.  Standardization and Quality Control of PCR Analyses , 2000, Clinical chemistry and laboratory medicine.

[4]  M. Neumaier,et al.  Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. International Federation of Clinical Chemistry Scientific Division Committee on Molecular Biology Techniques. , 1998, Clinical chemistry.

[5]  E Marubini,et al.  Confidence interval estimation for DNA and mRNA concentration by real-time PCR: A new environment for an old theorem. , 2004, The International journal of biological markers.

[6]  D. Stoppa-Lyonnet,et al.  External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E Marubini,et al.  Statistical Diagnostics Emerging from External Quality Control of Real-Time PCR , 2004, The International journal of biological markers.

[8]  J. Libeer.  Role of external quality assurance schemes in assessing and improving quality in medical laboratories. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[9]  J. Tait,et al.  Frequency of problems during clinical molecular-genetic testing. , 1999, American journal of clinical pathology.

[10]  Russell Higuchi,et al.  Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.

[11]  D. Seligson,et al.  Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.

[12]  S. Kitchen,et al.  A UK National External Quality Assessment Scheme (UK Neqas) for Molecular Genetic Testing for the Diagnosis of Familial Thrombophilia , 1999, Thrombosis and Haemostasis.

[13]  P. Ahmad-Nejad,et al.  Methodologic European external quality assurance for DNA sequencing: the EQUALseq program. , 2006, Clinical chemistry.

[14]  E. Dequeker,et al.  Genetic testing and quality control in diagnostic laboratories , 2000, Nature Genetics.

[15]  P. Mannucci,et al.  Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern , 2002, Thrombosis and Haemostasis.

[16]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[17]  P. Pignatti,et al.  Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance , 2004, Clinical chemistry and laboratory medicine.

[18]  M. Losekoot,et al.  A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease , 1999, European Journal of Human Genetics.

[19]  Mario Pazzagli,et al.  An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man™ probes , 2005, Clinical chemistry and laboratory medicine.